Current Report Filing (8-k)
June 17 2013 - 5:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 15, 2013
PROLOR
BIOTECH, INC.
(Exact Name of Registrant as Specified in
Its Charter)
Nevada |
001-34676 |
20-0854033 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
7 Golda
Meir Street
Weizmann Science Park
Nes-Ziona, Israel 74140 |
(Address of Principal Executive Office) |
Registrant’s telephone number, including area code (866)
644-7811
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On Saturday, June 15,
2013, and Sunday, June 16, 2013, PROLOR Biotech, Inc., a Nevada corporation (the “Company”), presented certain
poster presentations (the “Presentations”) at ENDO 2013, the 95th Annual Meeting of the Endocrine Society. Copies
of the Presentations are furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item
7.01.
The information contained
in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended.
ITEM 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number |
Description |
99.1 |
Poster Presentations |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
PROLOR BIOTECH, INC.
|
|
|
Date: June 17, 2013
|
By: |
/s/ Shai Novik |
|
|
Shai Novik
President
|
EXHIBIT
INDEX
Exhibit
Number |
Description |
99.1 |
Poster Presentations |
Prolor Biotech, Inc. (AMEX:PBTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Prolor Biotech, Inc. (AMEX:PBTH)
Historical Stock Chart
From Jul 2023 to Jul 2024